Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer

Antonio Rossi, Anna La Salvia, Massimo Di Maio

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.

Original languageEnglish
Pages (from-to)171-180
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Keywords

  • Afatinib
  • chemotherapy
  • EGFR
  • erlotinib
  • gefitinib
  • icotinib
  • metastatic
  • mutations
  • NSCLC
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this